Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-10 23:18 | 2025-10-08 | AGIO | Agios Pharmaceuticals Inc. | Scadden David | Director | OPT+S | $41.00 | 200 | $8,200 | 17,603 |
| 2025-10-11 02:17 | 2025-10-10 | ZVRA | ZEVRA THERAPEUTICS, INC. | McFarlane Neil F. | Director, Officer | OPT+S | $10.82 | 19,500 | $210,908 | 222,016 |
| 2025-10-10 23:01 | 2025-10-08 | OCUL | OCULAR THERAPEUTIX, INC | Anderman Todd | Officer | SELL | $12.34 | 11,132 | $137,369 | 87,568 |
| 2025-10-11 00:33 | 2025-10-09 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $50.57 | 59,900 | $3,029,335 | 1,206,578 |
| 2025-10-10 23:30 | 2025-10-08 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director | SELL | $2.42 | 121,791 | $294,552 | 8,260 |
| 2025-10-11 01:17 | 2025-09-12 | BGMS | Bio Green Med Solution, Inc. | Kua Khai Loon | 10% owner | SELL | $5.65 | 47,251 | $266,789 | 338,160 |
| 2025-10-11 01:16 | 2025-10-08 | BGMS | Bio Green Med Solution, Inc. | FITTERS Diversified Berhad | 10% owner | SELL | $5.29 | 142,000 | $751,606 | 557,158 |
| 2025-10-11 00:03 | 2025-10-09 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $446.81 | 8,000 | $3,574,443 | 130 |
| 2025-10-11 03:06 | 2025-10-08 | ACET | Adicet Bio, Inc. | ORBIMED ADVISORS LLC | 10% owner | BUY | $1.00 | 5,000,000 | $5,000,000 | 4,490,254 |
| 2025-10-10 23:21 | 2025-10-09 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Director | SELL | $50.77 | 25,000 | $1,269,235 | 104,644 |
| 2025-10-09 23:00 | 2025-10-08 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $850.27 | 101,420 | $86,234,870 | 94,547,580 |
| 2025-10-09 16:01 | 2025-10-08 | MLTX | MoonLake Immunotherapeutics | Bodenstedt Matthias | Officer | BUY | $9.09 | 10,870 | $98,808 | 627,536 |
| 2025-10-09 22:37 | 2024-09-13 | ZBIO | Zenas BioPharma, Inc. | Lu Hongbo | Director | BUY | $18.63 | 321,983 | $6,000,024 | 321,983 |
| 2025-10-09 23:22 | 2025-08-19 | HOOK | HOOKIPA Pharma Inc. | Peters Malte | Director, Officer | SELL | $0.82 | 25,172 | $20,684 | 54,347 |
| 2025-10-10 01:58 | 2025-10-07 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Officer | OPT+S | $46.08 | 12,500 | $576,001 | 166,571 |
| 2025-10-10 00:21 | 2025-10-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | Officer | SELL | $20.10 | 6,667 | $133,993 | 276,641 |
| 2025-10-09 20:37 | 2025-10-08 | URGN | UroGen Pharma Ltd. | Degnan Chris | Officer | OPT+S | $16.85 | 2,203 | $37,121 | 2,280 |
| 2025-10-09 23:15 | 2025-10-07 | ZBIO | Zenas BioPharma, Inc. | Fairmount Funds Management LLC | Director | BUY | $19.00 | 316,219 | $6,008,161 | 2,209,025 |
| 2025-10-09 23:07 | 2025-10-07 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Director | SELL | $70.14 | 90,000 | $6,312,501 | 500,621 |
| 2025-10-10 00:24 | 2025-10-07 | ZBIO | Zenas BioPharma, Inc. | MOULDER LEON O JR | Director, Officer | BUY | $20.85 | 36,928 | $769,949 | 36,928 |
| 2025-10-10 00:51 | 2025-10-07 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $89.94 | 20,000 | $1,798,782 | 5,287 |
| 2025-10-10 00:20 | 2025-10-07 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $63.43 | 3,375 | $214,091 | 103,901 |
| 2025-10-08 23:00 | 2025-10-07 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $848.01 | 26,795 | $22,722,401 | 94,649,000 |
| 2025-10-09 00:33 | 2025-10-06 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | Officer | OPT+S | $18.21 | 30,385 | $553,198 | 145,355 |
| 2025-10-09 00:33 | 2025-10-06 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | OPT+S | $18.06 | 50,500 | $911,843 | 202,641 |
| 2025-10-09 01:36 | 2025-10-06 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | SELL | $69.37 | 1,625 | $112,725 | 30,301 |
| 2025-10-09 01:37 | 2025-10-06 | IONS | IONIS PHARMACEUTICALS INC | Swayze Eric | Officer | SELL | $69.02 | 6,849 | $472,718 | 30,453 |
| 2025-10-09 00:37 | 2025-10-06 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | Officer | OPT+S | $14.52 | 11,000 | $159,719 | 48,317 |
| 2025-10-09 03:55 | 2025-10-06 | SPRB | SPRUCE BIOSCIENCES, INC. | Parkman Healthcare Partners LLC | 10% owner | SELL | $19.14 | 257 | $4,920 | 1,050 |
| 2025-10-09 03:55 | 2025-10-06 | SPRB | SPRUCE BIOSCIENCES, INC. | Parkman Healthcare Partners LLC | 10% owner | BUY | $17.91 | 256 | $4,585 | 1,307 |
| 2025-10-09 02:08 | 2025-10-06 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | Officer | OPT+S | $14.92 | 50,292 | $750,412 | 214,232 |
| 2025-10-09 04:00 | 2025-10-06 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $16.21 | 665,159 | $10,781,828 | 1,504,959 |
| 2025-10-09 00:35 | 2025-10-06 | ORIC | Oric Pharmaceuticals, Inc. | Chacko Jacob | Director, Officer | SELL | $12.32 | 37,461 | $461,520 | 531,419 |
| 2025-10-09 01:37 | 2025-10-06 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | OPT+S | $69.74 | 13,441 | $937,338 | 53,889 |
| 2025-10-09 01:36 | 2025-10-06 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | SELL | $69.26 | 437 | $30,268 | 179,572 |
| 2025-10-08 23:16 | 2025-10-07 | CARM | Carisma Therapeutics Inc. | Klichinsky Michael | Officer | OPT+S | $0.25 | 56,982 | $14,485 | 0 |
| 2025-10-09 04:08 | 2025-10-06 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | Director, Officer, 10% owner | OPT+S | $119.38 | 45,384 | $5,418,060 | 7,229 |
| 2025-10-08 13:50 | 2025-10-06 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director | SELL | $2.47 | 139,412 | $344,222 | 68,848 |
| 2025-10-08 23:31 | 2025-10-07 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $451.35 | 8,000 | $3,610,770 | 130 |
| 2025-10-09 02:48 | 2025-10-01 | RMTI | ROCKWELL MEDICAL, INC. | Hunter Heather | Officer | SELL | $1.19 | 2,868 | $3,413 | 135,391 |
| 2025-10-08 23:10 | 2025-10-06 | AIMD | Ainos Inc. | Taiwan Carbon Nano Technology Corp | 10% owner | SELL | $3.59 | 7,000 | $25,130 | 1,037,206 |
| 2025-10-07 23:00 | 2025-10-06 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $850.22 | 161,183 | $137,041,655 | 94,675,795 |
| 2025-10-07 15:56 | 2025-10-03 | IMRX | Immuneering Corp | Feinberg Peter | Director | BUY | $6.67 | 7,500 | $50,025 | 156,766 |
| 2025-10-07 23:26 | 2025-10-03 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | OPT+S | $25.07 | 10,000 | $250,650 | 11,831 |
| 2025-10-07 23:11 | 2025-10-03 | RNA | Avidity Biosciences, Inc. | Mosbrooker Eric | Officer | OPT+S | $45.38 | 6,562 | $297,771 | 55,000 |
| 2025-10-07 23:26 | 2025-10-03 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. MD | Director | SELL | $25.09 | 42,461 | $1,065,206 | 49,124 |
| 2025-10-08 01:14 | 2025-10-03 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.78 | 20,200 | $35,964 | 1,817,896 |
| 2025-10-08 00:00 | 2025-10-03 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Director | SELL | $29.99 | 49,546 | $1,485,790 | 785,480 |
| 2025-10-08 03:22 | 2025-10-06 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | Officer | SELL | $13.99 | 107 | $1,497 | 17,026 |
| 2025-10-07 23:32 | 2025-10-06 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $450.24 | 22,500 | $10,130,438 | 0 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.